GLP-1 RAs augment insulin secretion after meals and inhibit glucagon production from pancreatic alpha cells at hyper- or euglycemia
It should include: Clinical screening for contraindications, interacting medicines, and relevant medical history
For retatrutide, were getting, I think, maximum benefit for a single asset. Kopach anticipates sharing the results of seven Phase III studies by the end of 2026
Blood glucose should be closely monitored
Differences between GLP-1R agonists GLP-1R agonists already in the market and others in development present the same mode of action and, having the same pleiotropic effects of native GLP-1, the differences in clinical profiles between them are related to differences in pharmacokinetics, structure and size of each formulation
Understanding their current regulatory positions provides insight into their availability, pricing, and potential timeline for expanded clinical use